239 related articles for article (PubMed ID: 28486358)
1. Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.
Greco PS; Bazzi AA; McLean K; Reynolds RK; Spencer RJ; Johnston CM; Liu JR; Uppal S
Obstet Gynecol; 2017 Jun; 129(6):979-985. PubMed ID: 28486358
[TBL] [Abstract][Full Text] [Related]
2. Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Salinaro JR; McQuillen K; Stemple M; Boccaccio R; Ehrisman J; Lorenzo AM; Havrilesky L; Secord AA; Galvan Turner V; Moore KN; Davidson B
Int J Gynecol Cancer; 2020 Apr; 30(4):491-497. PubMed ID: 32054646
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study.
Oxley SG; Achampong YA; Sambandan N; Hughes DJ; Thomas M; Lockley M; Olaitan A
Acta Obstet Gynecol Scand; 2021 Nov; 100(11):2091-2096. PubMed ID: 34486103
[TBL] [Abstract][Full Text] [Related]
4. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Li S; Bercow AS; Falzone M; Kalyanaraman R; Worley MJ; Feltmate CM; Pelletier A; Elias KM
Gynecol Oncol; 2021 Aug; 162(2):353-359. PubMed ID: 34092412
[TBL] [Abstract][Full Text] [Related]
5. Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
Moufarrij S; Sassine D; Basaran D; Jewell EL
Gynecol Oncol; 2023 Mar; 170():167-171. PubMed ID: 36701837
[TBL] [Abstract][Full Text] [Related]
6. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
8. Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
Wagner BE; Langstraat CL; McGree ME; Weaver AL; Sarangi S; Mokri B; Dowdy SC; Cliby WA; Kumar A; Bakkum-Gamez JN
Gynecol Oncol; 2019 Feb; 152(2):286-292. PubMed ID: 30471900
[TBL] [Abstract][Full Text] [Related]
9. Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer.
Chokshi SK; Gaughan JP; Krill L
J Thromb Thrombolysis; 2022 Jan; 53(1):202-207. PubMed ID: 34185227
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Yoon SH; Kim YB
PLoS One; 2021; 16(4):e0250723. PubMed ID: 33909674
[TBL] [Abstract][Full Text] [Related]
11. Venous Thromboembolism in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian Cancer and Impact on Survival.
Black KA; Ghosh S; Singh N; Chu P; Pin S
J Obstet Gynaecol Can; 2021 Dec; 43(12):1380-1387. PubMed ID: 34087490
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
13. Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea.
Shin W; Lee S; Lim MC; Jung J; Kim HJ; Cho H
Cancer Med; 2021 Mar; 10(6):2045-2053. PubMed ID: 33638309
[TBL] [Abstract][Full Text] [Related]
14. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Shibutani T; Nagao S; Suzuki K; Kaneda M; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Sudo T; Yamaguchi S
Int J Clin Oncol; 2020 Mar; 25(3):502-507. PubMed ID: 31677021
[TBL] [Abstract][Full Text] [Related]
16. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
Nicklin JL; McGrath S; Tripcony L; Garrett A; Land R; Tang A; Perrin L; Chetty N; Jagasia N; Crandon AJ; Nascimento M; Walker G; Sanday K; Obermair A
Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):651-658. PubMed ID: 28718942
[TBL] [Abstract][Full Text] [Related]
17. Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Shafa A; Watkins AB; McGree ME; Weroha SJ; Wahner Hendrickson AE; Block MS; Langstraat CL; McBane RD; Bakkum-Gamez JN; Kumar A
Gynecol Oncol; 2023 Sep; 176():36-42. PubMed ID: 37442024
[TBL] [Abstract][Full Text] [Related]
18. Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Basaran D; Boerner T; Suhner J; Sassine D; Liu Y; Grisham RN; Tew WP; Gardner GJ; Zivanovic O; Sonoda Y; Long Roche K; Chi DS; Abu-Rustum NR; Soff GA; Jewell EL
Gynecol Oncol; 2021 Oct; 163(1):36-40. PubMed ID: 34312001
[TBL] [Abstract][Full Text] [Related]
19. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study.
Dahm-Kähler P; Palmqvist C; Staf C; Holmberg E; Johannesson L
Gynecol Oncol; 2016 Aug; 142(2):211-6. PubMed ID: 27238084
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
